You can buy or sell bluebird bio and other stocks, options, ETFs, and crypto commission-free!
bluebird bio, Inc. Common Stock, also called bluebird bio, is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Read More Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
bluebird bio Statement on European Regulatory Status of LentiGlobin™
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 25, 2019--A third party press release was issued today stating that the EMA (European Medicines Agency) issued an approval for the conditional Marketing Authorization Application (MAA) for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia (TDT). LentiGlobin for TDT is scheduled to be reviewed as part of the CHMP (Committee on Human Medicinal Products) meeting from March 25 – 28, however no opinion has bee...
Simply Wall StMar 21
Is bluebird bio, Inc.’s (NASDAQ:BLUE) CEO Salary Justified?
Nick Leschly became the CEO of bluebird bio, Inc. (NASDAQ:BLUE) in 2010. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider the growth in the business. And finally we will reflect on how common stockholders have fared in the last few years, as a secondary measure of performance. The aim of all this is to consider the appropriateness of CEO pay levels. Check out our latest analysis for bluebird bio How Does Nick Leschly’s Compensatio...
The Motley FoolMar 11
Here's Why bluebird bio Gained 16.3% in February
What happened Shares of bluebird bio (NASDAQ:BLUE) rose over 16% last month, according to data from S&P Global Market Intelligence. The biopharma reported fourth-quarter and full-year 2018 operating results. As a pre-commercial company, there wasn't much in the way of financial numbers to review, although the business did begin 2019 with $1.9 billion in cash, cash equivalents, and marketable securities. Investors were more excited about the update on the company's late-stage pipeline. CEO Nick Leschly sai...
Expected May 1, After Hours